Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities von Alloo, A., Sheu, J., Butrynski, J.E., DeAngelo, D.J., George, S., Murphy, G.F., LeBoeuf, N.R.

Volltext

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib von Ganjoo, K.N., Villalobos, V.M., Kamaya, A., Fisher, G.A., Butrynski, J.E., Morgan, J.A., Wagner, A.J., D'Adamo, D., McMillan, A., Demetri, G.D., George, S.

Volltext

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kin... von Ben-Ami, E., Barysauskas, C.M., von Mehren, M., Heinrich, M.C., Corless, C.L., Butrynski, J.E., Morgan, J.A., Wagner, A.J., Choy, E., Yap, J.T., Van den Abbeele, A.D., Solomon, S.M., Fletcher, J.A., Demetri, G.D., George, S.

Volltext

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial von Bui-Nguyen, B, Butrynski, J.E, Penel, N, Blay, J.Y, Isambert, N, Milhem, M, Kerst, J.M, Reyners, A.K.L, Litière, S, Marréaud, S, Collin, F, van der Graaf, W.T.A

Volltext

Esophageal gastrointestinal stromal tumor: report of 7 patients von Shinagare, A B, Zukotynski, K A, Krajewski, K M, Jagannathan, J P, Butrynski, J, Hornick, J L, Ramaiya, N H

Volltext

P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study von Evangelist, M., Jotte, R., Spira, A., Waterhouse, D., Ali, K., Alwardt, S., Bullock, S., Butrynski, J., Espirito, J., Fitzgerald, C., Hakimian, D., Larson, T., Meshad, M., Neubauer, M., Paschold, J., Robert, N., Walberg, J., Coleman, R.

Volltext

G-protein beta gamma dimers. Membrane targeting requires subunit coexpression and intact gamma C-A-A-X domain von Simonds, W F, Butrynski, J E, Gautam, N, Unson, C G, Spiegel, A M

Volltext

[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors von HAWKINS, Douglas S, SCHUETZE, Scott M, BUTRYNSKI, James E, RAJENDRAN, Joseph G, VERNON, Cheryl B, CONRAD, Ernest U, EARY, Janet F

Volltext

High rates of histopathologic discordance in sarcoma with implications for clinical care von Raut, C. P., George, S., Hornick, J. L., Butrynski, J. E., Morgan, J. A., Ready, J., Nascimento, A. F., Fletcher, C. D., Demetri, G. D., Baldini, E. H.

Volltext

A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma von Cranmer, L. D., Ganjoo, K. N., Adkins, D., Reed, D. R., Okuno, S. H., Butrynski, J. E., Rushing, D. A., Lorente, G. A., Kroll, S., Chawla, S. P.

Volltext

The G protein connection: molecular basis of membrane association von Spiegel, Allen M., Backlund, Peter S., Butrynski, James E., Jones, Teresa L.Z., Simonds, William F.

Volltext

Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors von Quek, R. H., Morgan, J. A., Shapiro, G., Butrynski, J. E., Wang, Q., Huftalen, T., Jederlinic, N., Wagner, A. J., Demetri, G. D., George, S.

Volltext

A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) von Trent, J. C., Wathen, K., von Mehren, M., Samuels, B. L., Staddon, A. P., Choy, E., Butrynski, J. E., Chugh, R., Chow, W. A., Rushing, D. A., Forscher, C. A., Baker, L. H., Schuetze, S.

Volltext

Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma von Cranmer, L. D., Chawla, S. P., Rushing, D. A., Butrynski, J. E., Okuno, S. H., Adkins, D., Langmuir, V. K., Lorente, G. A., Kroll, S., Ganjoo, K. N.

Volltext

SWOG0345: Prospective phase II trial of imatinib in dermatofibrosarcoma protuberans (DFSP) von Schuetze, S. M., Rankin, C. A., Rubin, B. P., Butrynski, J. E., Borden, E. C.

Volltext

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU) von George, S., von Mehren, M., Heinrich, M. C., Wang, Q., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Tap, W. D., Manola, J., Yap, J. T., Van Den Abbeele, A. D., Solomon, S., Fletcher, J. A., Demetri, G. D.

Volltext

Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S von Butrynski, J. E., Duh, M. S., Fournier, A., Moyneur, E., Dial, E., Neary, M. P., Demetri, G. D.

Volltext

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial von Keohan, M. L., Morgan, J. A., D’Adamo, D. R., Harmon, D., Butrynski, J. E., Wagner, A. J., Schwartz, G. K., Maki, R. G., Demetri, G. D., George, S.

Volltext

G-protein βγ dimers : membrane targeting requires subunit coexpression and intact γ C-A-A-X domain von SIMONDS, W. F, BUTRYNSKI, J. E, GAUTAM, N, UNSON, C. G, SPIEGEL, A. M

Volltext

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib von Janeway, K. A., Matthews, D. C., Butrynski, J. E., D’Amato, G. Z., Agresta, S., Garrett, C., Corless, C. L., Albritton, K. H., Demetri, G. D.

Volltext